ACHILLION PHARMACEUTICALS INC (ACHN) Stock Price, Forecast & Analysis
USA - NASDAQ:ACHN -
ACHN Key Statistics, Chart & Performance
The current stock price of ACHN is 6.76 null. In the past month the price increased by 10.1%. In the past year, price increased by 201.79%.
ACHN Latest News, Press Relases and Analysis
About ACHN
Company Profile
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.
Company Info
ACHILLION PHARMACEUTICALS INC
300 GEORGE STREET
NEW HAVEN CT 06511
CEO: Joseph Truitt
Phone: 203-624-7000
ACHILLION PHARMACEUTICALS INC / ACHN FAQ
What does ACHILLION PHARMACEUTICALS INC do?
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.
What is the stock price of ACHILLION PHARMACEUTICALS INC today?
The current stock price of ACHN is 6.76 null. The price increased by 10.28% in the last trading session.
Does ACHN stock pay dividends?
ACHN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACHN stock?
ACHN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in ACHILLION PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACHN.
What is ACHILLION PHARMACEUTICALS INC worth?
ACHILLION PHARMACEUTICALS INC (ACHN) has a market capitalization of 946.72M null. This makes ACHN a Small Cap stock.
Can you provide the ownership details for ACHN stock?
You can find the ownership structure of ACHILLION PHARMACEUTICALS INC (ACHN) on the Ownership tab.
ACHN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ACHN. When comparing the yearly performance of all stocks, ACHN is one of the better performing stocks in the market, outperforming 98.56% of all stocks.
ACHN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACHN. No worries on liquidiy or solvency for ACHN as it has an excellent financial health rating, but there are worries on the profitability.
ACHN Financial Highlights
Over the last trailing twelve months ACHN reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 3.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.55% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |